Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.43 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21238766 | 0.90 | DRD2 (0.35) | LRRK2OGADRD2DRD4DRD3 | |
| SCHEMBL24923652 | 0.86 | HSP90AA1 (0.37) | LRRK2DRD2DRD4DRD3 | |
| SCHEMBL24837078 | 0.85 | ALDH1A2 (0.33) | LRRK2JAK2NTRK1 | |
| SCHEMBL24703895 | 0.83 | LRRK2 (0.35) | LRRK2OGAFLT3SYKIRAK4 | |
| SCHEMBL17998057 | 0.83 | OGA (0.39) | LRRK2OGAFLT3SYKIRAK4 | |
| SCHEMBL25556777 | 0.82 | ALOX15 (0.40) | LRRK2FLT3SYKDRD2DRD4 | |
| SCHEMBL25556775 | 0.82 | CHRNB2 (0.44) | JAK2 | |
| SCHEMBL18012432 | 0.81 | LRRK2 (0.43) | LRRK2OGAFLT3SYKIRAK4 | |
| SCHEMBL23996983 | 0.81 | LRRK2 (0.44) | LRRK2OGAIRAK4JAK2JAK1 | |
| SCHEMBL25556783 | 0.79 | KDM5A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389004-A1 | FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | EMD Serono Research and Development Institute, Inc. | 2022-12-08 | — | — | US | disclosed |
| EP-3253763-B1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389004-A1 | FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, SYK, ABL1 | LRRK2 465/4885OGA 3411/4885FLT3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.